Radiopharmaceutical firm Syncor International received 510(k) clearance from the Food and Drug Administration last month for its iodine-125 seeds, the company’s first product in a line of radioactive implants for treatment of prostate cancer.
Radiopharmaceutical firm Syncor International received 510(k) clearance from the Food and Drug Administration last month for its iodine-125 seeds, the companys first product in a line of radioactive implants for treatment of prostate cancer.
Woodland Hills, CA-based Syncor began to develop the seeds seven months ago, and will market its brachytherapy seed products in the U.S. under the trade name PharmaSeed, according to Robert Funari, president and CEO. In the pipeline is a product using palladium-103, for use with more aggressive tumors.
In other Syncor news, the company plans to begin a stock repurchase program it announced in July. Syncor has 500,800 shares authorized for purchase. When it will begin buying shares and how many it will buy has not been determined.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
New Study Finds Racial Disparities with Pre-Op Breast MRI and Positive Surgical Margin Rates
November 8th 2024In addition to a lower rate of preoperative breast MRI use, emerging research found that Black women with breast cancer who didn’t have a preoperative MRI had a higher positive surgical margin rate than White women with no preoperative MRI.